Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/59096
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus |
Author: | Lobigs, M. Larena, M. Alsharifi, M. Lee, E. Pavy, M. |
Citation: | Journal of Virology, 2009; 83(6):2436-2445 |
Publisher: | Amer Soc Microbiology |
Issue Date: | 2009 |
ISSN: | 0022-538X 1098-5514 |
Statement of Responsibility: | Mario Lobigs, Maximilian Larena, Mohammed Alsharifi, Eva Lee and Megan Pavy |
Abstract: | The Japanese encephalitis virus (JEV) serocomplex, which also includes Murray Valley encephalitis virus (MVEV), is a group of antigenically closely related, mosquito-borne flaviviruses that are responsible for severe encephalitic disease in humans. While vaccines against the prominent members of this serocomplex are available or under development, it is unlikely that they will be produced specifically against those viruses which cause less-frequent disease, such as MVEV. Here we have evaluated the cross-protective values of an inactivated JEV vaccine (JE-VAX) and a live chimeric JEV vaccine (ChimeriVax-JE) against MVEV in two mouse models of flaviviral encephalitis. We show that (i) a three-dose vaccination schedule with JE-VAX provides cross-protective immunity, albeit only partial in the more severe challenge model; (ii) a single dose of ChimeriVax-JE gives complete protection in both challenge models; (iii) the cross-protective immunity elicited with ChimeriVax-JE is durable (>5 months) and broad (also giving protection against West Nile virus); (iv) humoral and cellular immunities elicited with ChimeriVax-JE contribute to protection against lethal challenge with MVEV; (v) ChimeriVax-JE remains fully attenuated in immunodeficient mice lacking type I and type II interferon responses; and (vi) immunization with JE-VAX, but not ChimeriVax-JE, can prime heterologous infection enhancement in recipients of vaccination on a low-dose schedule, designed to mimic vaccine failure or waning of vaccine-induced immunity. Our results suggest that the live chimeric JEV vaccine will protect against other viruses belonging to the JEV serocomplex, consistent with the observation of cross-protection following live virus infections. |
Keywords: | Animals Mice, Inbred C57BL Mice, Knockout Humans Mice Encephalitis Virus, Japanese Encephalitis Virus, Murray Valley Encephalitis, Arbovirus Vaccines, Synthetic Vaccines, Attenuated Antibodies, Viral Immunization, Secondary Survival Analysis Cross Reactions Immunologic Memory Time Factors Female Male |
Rights: | Copyright © 2009, American Society for Microbiology. All Rights Reserved. |
DOI: | 10.1128/JVI.02273-08 |
Published version: | http://dx.doi.org/10.1128/jvi.02273-08 |
Appears in Collections: | Aurora harvest Molecular and Biomedical Science publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.